Last reviewed · How we verify
Host DNA Methylation for Endometrial Cancer Screening
Based on the previous study of NCT04651738, we performed this trial to further confirm the accuracy of host DNA CDO1 and CELF4 methylation for endometrial cancer screening in a multi-center cohort. Thirteen hospitals, including Peking Union Medical College Hospital, would enroll eligible patients in this study. The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation, and the results will compared with the endometrial histological pathology, which is achieved after collection of cervical cytology, by surgeries including hysteroscopy, dilation and curettage, total hysterectomy and others. The methylation testing would be double-blinded in operators and analysts. The study will enroll at least 10,000 patients.
Details
| Lead sponsor | Lei Li |
|---|---|
| Status | UNKNOWN |
| Enrolment | 10000 |
| Start date | Sun Mar 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Cancer Screening
- Endometrial Cancer
- DNA Methylation
- Cervical Cytology
- Liquid Biopsy
- Cohort Study
Interventions
- DNA methylation testing
Countries
China